XORTX Therapeutics (XRTX) vs. Its Peers Head to Head Review

XORTX Therapeutics (NASDAQ:XRTX) is one of 247 publicly-traded companies in the “MED – DRUGS” industry, but how does it weigh in compared to its rivals? We will compare XORTX Therapeutics to similar companies based on the strength of its analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Valuation and Earnings

This table compares XORTX Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XORTX Therapeutics	N/A	-$2.66 million	-1.01
XORTX Therapeutics Competitors	$1.20 billion	$102.44 million	-4.51

XORTX Therapeutics’ rivals have higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 43.9% of shares of all “MED – DRUGS” companies are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by company insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares XORTX Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-120.32%	-90.53%
XORTX Therapeutics Competitors	-22,657.44%	-150.65%	-22.79%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for XORTX Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1	0	0	0	1.00
XORTX Therapeutics Competitors	2889	4052	10322	470	2.47

As a group, “MED – DRUGS” companies have a potential upside of 55.02%. Given XORTX Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe XORTX Therapeutics has less favorable growth aspects than its rivals.

Risk & Volatility

XORTX Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, XORTX Therapeutics’ rivals have a beta of -0.38, indicating that their average share price is 138% less volatile than the S&P 500.

Summary

XORTX Therapeutics rivals beat XORTX Therapeutics on 9 of the 13 factors compared.

XORTX Therapeutics Company Profile

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.